Adiso debuts with inflammatory pipeline, $60M from Morningside

After several years of incubation in stealth, Morningside Ventures has launched Adiso with three potential first-in-class programs to treat inflammatory diseases.

Adiso Therapeutics Inc. made its public debut Thursday with sole investor Morningside Ventures having already invested $60 million in a series A round, which helped the company bring its first two programs into the clinic...